Cascade of care during the first 36 months of the treatment as prevention for hepatitis C (TraP HepC) program in Iceland: A population-based study

The Lancet: Gastroenterology & HepatologyOlafsson S, Fridriksdottir RH, Love TJ, et al. | June 24, 2021

Advertisement

In February, 2016, a nationwide HCV elimination program known as treatment as prevention for hepatitis C (TraP HepC) was launched in Iceland, with the objective to maximise diagnosis and treatment access. Researchers herein performed a population-based study with the aim to analyze the HCV cascade of care in the first 3 years of the program. Direct-acting antiviral (DAA) therapy was offered to participants aged 18 years or older with permanent residence in Iceland and PCR-confirmed HCV. A multidisciplinary team approach was used in this program in which priority was given to people who inject drugs. Simultaneous scaling up of nationwide awareness campaigns, improved access to testing, and harm reduction services was done. Outcomes suggest achievement of the core service coverage targets for 2030 set by WHO by using a multidisciplinary public health approach, involving tight integration with addiction treatment services. Because of these achievements, Iceland has been acknowledged as one of the first nations to subsequently achieve the WHO goal of eliminating HCV as a public health threat.

Read the full article on The Lancet: Gastroenterology & Hepatology

Advertisement